Toxin News and Research

RSS

Allergan files declaratory relief action to allow it to share relavant information on BOTOX

Allergan, Inc. today filed a declaratory relief action in the United States District Court for the District of Columbia seeking a ruling that would allow Allergan to proactively share truthful and relevant information with the medical community to assist physicians in evaluating the risks and benefits of BOTOX (onabotulinumtoxinA) for certain “off-label” therapeutic uses.

5 Oct 2009

Nature's best mercury fighters: Bacteria

Mercury pollution is a persistent problem in the environment. Human activity has lead to increasingly large accumulations of the toxic chemical, especially in waterways, where fish and shellfish tend to act as sponges for the heavy metal.

5 Oct 2009

Neogen announces first-quarter results of fiscal 2010

Neogen Corporation announced today that its revenues for the first quarter of FY 2010, which ended Aug. 31, increased 12% from the previous year's first quarter to $32,347,000. First quarter net income increased 18% from the prior year's $3,733,000 to $4,395,000, or to $0.29 per share in the current year compared to the previous year's $0.25.

25 Sep 2009

Morphotek receives NIAID grant to develop human mAb therapies against staphylococcal-derived pathogens

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that it was awarded $843,289 in funding from the National Institutes of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to support the development of human monoclonal antibody (mAb) therapies against staphylococcal-derived toxin(s).

23 Sep 2009

Tregs to set the pace of recovery after serious lung injury

After more than 50 experiments in mice, medical scientists at Johns Hopkins have mapped out the basic steps taken by a particular set of white blood cells in setting the pace of recovery after serious lung injury.

22 Sep 2009

NIAID awards DOR BioPharma a $9M grant to develop thermostable and rapidly acting vaccines

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that it has been awarded an approximate $9.4 Million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).

21 Sep 2009

Ipsen's Azzalure muscle relaxant receives Spanish AEMPS marketing approval

Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Euronext: IPN), an international innovation-driven specialty pharmaceutical group, today announced that Azzalure® (botulinum toxin type A manufactured by Ipsen), a local muscle relaxant specifically developed for aesthetic use, has received a marketing authorization in Spain from the Spanish Medicines and Healthcare products Agency (AEMPS) for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown (vertical lines between the eyebrows), in adult men and women aged 65 years and under, when the severity of these lines has an important psychological impact on the patient.

21 Sep 2009

Wyeth and Ambrx collaborate to produce the next generation of biologic drugs

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Ambrx Inc. today announced the formation of a worldwide alliance to discover, develop, and commercialize protein drug candidates for three undisclosed targets in multiple therapeutic areas. The alliance will capitalize on Ambrx's recent breakthroughs in applying its protein medicinal chemistry platform to proteins produced in mammalian cells such as antibodies and antibody-toxin conjugates.

19 Sep 2009

Universal Detection Technology to showcase its TS-10-5-agent biodetection kit

Universal Detection Technology, a developer of early-warning monitoring technologies and counter-terrorism training programs to protect people from bioterrorism and other infectious health threats, announced today that it will be showcasing its TS-10-5-agent biodetection kit at ASIS International 2009 in Anaheim, California.

18 Sep 2009

Researchers examine new method for controlling soybean aphids

Two Iowa State University researchers are examining a new method of controlling soybean aphids without the use of chemical pesticides.

16 Sep 2009

Scarab Genomics and Neoclone sign license agreement

Scarab Genomics, a leader in E coli technology, has entered into a license agreement with NeoClone to market and distribute their proprietary antibodies against Shiga toxin.

11 Sep 2009

Brain's SCN is the master clock that synchronizes other biological clocks in the body

Alexis Webb enters a small room at Washington University in St. Louis with walls, floor and ceiling painted dark green, shuts the door, turns off the lights and bends over a microscope in a black box draped with black cloth. Through the microscope, she can see a single nerve cell on a glass cover slip glowing dimly.

10 Sep 2009

New probiotic provides protection against the fatal E. coli disease

Researchers in Australia are developing diversionary tactics to fool disease-causing bacteria in the gut. Many bacteria, including those responsible for major gut infections, such as cholera, produce toxins that damage human tissues when they bind to complex sugar receptors displayed on the surface of cells in the host's intestine.

8 Sep 2009

COPD patients to have better protection against pneumonia with new vaccine

A new vaccine against pneumonia may offer better protection from chronic obstructive pulmonary disease (COPD) patients than the currently accepted vaccine, according to recent research that will be published in the September 15 issue of the American Journal of the Respiratory and Critical Care Journal, a publication of the American Thoracic Society.

8 Sep 2009

Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier

Earlier this year, researchers at the University of Washington reported that they had developed a toxin-nanoparticle combination that inhibits brain cancer invasion when added to tumor cells growing in culture.

7 Sep 2009

Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice

Nanoparticle delivery of diphtheria toxin-encoding DNA that expresses selectively in ovarian cancer cells reduced the burden of ovarian tumors in mice, and researchers expect that this therapy could be tested in humans with advanced ovarian cancer within 18 to 24 months, according to a report in Cancer Research. If additional tests are successful, these finding could lead to a new treatment for ovarian cancer, which now causes more than 15,000 deaths each year in the United States. Because it is usually diagnosed at a relatively late stage, ovarian cancer is one of the most deadly forms of the disease.

7 Sep 2009

Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth

When bees sting, they pump into their victims a peptide toxin called melittin that destroys cell membranes. Now, by encapsulating this extremely potent molecule within a nanoparticle, researchers at the Washington University School of Medicine in St. Louis have created a potential new type of anticancer therapy with the potential to target a wide range of tumors. This work was reported in the Journal of Clinical Investigation.

7 Sep 2009

New protein fragments identified for anthrax vaccine development

Researchers at Albert Einstein College of Medicine of Yeshiva University have identified two small protein fragments that could be developed into an anthrax vaccine that may cause fewer side effects than the current vaccine.

4 Sep 2009

rPA anthrax vaccine and its Valortim anthrax anti-toxin program data presented

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that data from the Company's third generation recombinant protective antigen (rPA) anthrax vaccine program and its Valortim((R)) anthrax anti-toxin program were presented at the Bacillus - ACT 2009 meeting, August 30 - September 3, 2009, organized by the American Society for Microbiology.

4 Sep 2009

Green to Grow calls for support of the California Toxics-Free Babies and Toddlers Act

Green to Grow (www.greentogrow.com), a leading Los Angeles-based manufacturer of BPA-free baby bottles that provide a safe alternative to polycarbonate products containing Bisphenol A (BPA) - a chemical currently banned in Canada, Minnesota, Connecticut and under scrutiny in several European nations - is urging the public and California Assembly members to support the Toxics-Free Babies and Toddlers Act (SB 797).

3 Sep 2009

Toxin News and Research

Allergan files declaratory relief action to allow it to share relavant information on BOTOX

Nature's best mercury fighters: Bacteria

Neogen announces first-quarter results of fiscal 2010

Morphotek receives NIAID grant to develop human mAb therapies against staphylococcal-derived pathogens

Tregs to set the pace of recovery after serious lung injury

NIAID awards DOR BioPharma a $9M grant to develop thermostable and rapidly acting vaccines

Ipsen's Azzalure muscle relaxant receives Spanish AEMPS marketing approval

Wyeth and Ambrx collaborate to produce the next generation of biologic drugs

Universal Detection Technology to showcase its TS-10-5-agent biodetection kit

Researchers examine new method for controlling soybean aphids

Scarab Genomics and Neoclone sign license agreement

Brain's SCN is the master clock that synchronizes other biological clocks in the body

New probiotic provides protection against the fatal E. coli disease

COPD patients to have better protection against pneumonia with new vaccine

Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier

Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice

Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth

New protein fragments identified for anthrax vaccine development

rPA anthrax vaccine and its Valortim anthrax anti-toxin program data presented

Green to Grow calls for support of the California Toxics-Free Babies and Toddlers Act

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News